NAUT → $4.00 by Jan 3, 2027.

Two analyst initiations: Roth Capital (Buy, $3.50 PT) and Leerink (Outperform, $4 PT) A Nature Methods paper validating their Voyager platform for large-scale proteoform analysis, with a goal of \~20 proteoform assays by mid-2028 Volume way above average, plus an amended 13D/A from a major holder **Why I think there's real potential** Proteomics is still far behind genomics in what we can actually measure. If Voyager works at scale, it could matter a lot for drug discovery and diagnostics, especially …